RE:RE:RE:Steady Accumulation, asks disappearing...Was just written up on InMed. InMed Pharmaceuticals (CSE:C.IN, Stock Forum), formerly Cannabis Technologies, has been eating its Wheaties of late, rocketing up from as low as $0.12 in late January to $0.30 today, on the back of continued good news out of its research activities. The company has added INM-750 to its therapy roster, this one used for the treatment of Epidermolysis Bullosa Simplex (EBS), a rare skin disorder The company is moving to pre-clinical trials of the treatment and add to its existing glaucoma and arthritis therapies. The man behind InMed’s research platform, Dr Sazzad Hossain, Ph.D, M.SC, said in a news release, "EBS is a rare keratin mutation-related disease with no FDA approved treatment. The only options available to patients are wound care, pain management, and preventative bandaging. More severe forms of the disease lead to scarring, disfigurement, disability, and early death, usually before the age of 30." InMed stock dropped hard in the last several months as a large stakeholder rolled out a long dumping, giving long holders a value buy-in. The recent upward shift has included a large amount of stock purchased out of the US and shows no sign of slowing volume. Sob story: I held InMed stock late last year and just couldn’t sit tight through the long slide so I, regretfully, bailed before bottom. As we all know, the market punishes such abject cajone withdrawal, so I missed a large part of the run but am back in and holding for the long haul. Dr Sazzad is going to make retirement comfy. Interesting side note: Those who got in on the $500k PP at $0.10 a few weeks ago are laughing..